Pediatric Hematology/Oncology

Chemotherapy

Questions discussed in this category

How would you approach the prevention of irinotecan-induced diarrhea in a patient who previously experienced a diffuse rash with cefixime?

What alternatives to cephalosporins would you consider? Do you consider allergy testing?

1 Answer available

What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?

Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...

2 Answers available

Does the presence of asparaginase antibodies on Granger Genetics testing indicate need to switch asparaginase formulations?

1 Answer available

What are best practices for oncologists during the national platinum shortage?

Please specify how your institution is allocating resources now or will be soon.

13 Answers available

In a patient with HR B ALL and severe pancreatitis due to peg-asparaginase, how do you assess the impact of peg discontinuation on risk of relapse?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

2 Answers available

When using daratumumab in the setting of post-transplant red cell aplasia or post-transplant immune-mediated cytopenias, do you hold the drug for certain ANC parameters?

1 Answer available

What adjustments, if any, do you make to chemotherapy regimens for patients with chromosomal breakage disorders who develop malignancy?

Are there particular drugs you avoid or dose-adjustments that are recommended?

1 Answer available

How do you manage patients with chemotherapy-induced paronychia?

1 Answer available

Papers discussed in this category

Cancers (Basel), 2022 Apr 14

Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders.

The Lancet. Oncology, 2017-09

Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.

J Clin Oncol, 2020 Apr 10

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Journal of the National Cancer Institute, 2016-06

An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.

Pediatrics, 2014 Feb 02

Chemotherapy drug shortages in pediatric oncology: a consensus statement.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

The Journal of urology, 2018-12

Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.

N. Engl. J. Med.,

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Lancet Oncol., 2014 Feb 18

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

NEJM Evidence, 2022 Jun 1

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Br J Cancer, 2014 Apr 15

Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.

Cancer, 2011-06-15

Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Eur J Cancer, 2017 Nov 28

Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Lancet Oncol, 2021 Jan 18

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

J Clin Oncol, 2021 Apr 19

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.

J Clin Oncol, 2003 Jul 01

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.

Pediatric blood & cancer, 2015-06

Clinical application of asparaginase activity levels following treatment with pegaspargase.

Leukemia & lymphoma, 2018-08

Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.

Haematologica, 2016 Mar

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.

Eur Heart J, 2022 Nov 01

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

JACC. Heart failure, 2022 Jun 08

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

Cardio-oncology (London, England), 2021 Sep 27

Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.

JACC. CardioOncology, 2023 Jun 20

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2001 Aug

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Pediatric Hematology/Oncology

Chemotherapy

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology